Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.

Blood cancer journal·2026
Same author

Decreased frequency and inflammatory change of FoxP3+ regulatory T cells in immunopathogenesis of human acute graft-versus-host disease.

The Korean journal of internal medicine·2025
Same author

Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide.

Cancer research and treatment·2025
Same author

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.

Blood·2025
Same author

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study.

Cancer research and treatment·2024
Same author

Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.

The Korean journal of internal medicine·2024
Same journal

Primary breast follicular lymphoma without a BCL2 rearrangement: insights into extranodal lymphoma biology.

Blood research·2026
Same journal

Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.

Blood research·2026
Same journal

Novel treatment strategies in acute myeloid leukemia.

Blood research·2026
Same journal

Cross-cultural validation and reliability of the Korean version of the Haemophilia Activities List.

Blood research·2026
Same journal

Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention.

Blood research·2026
Same journal

Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification.

Blood research·2026
See all related articles

Related Experiment Video

Updated: Dec 13, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.5K

Extranodal NK/T cell lymphoma.

Seong Hyun Jeong1

  • 1Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.

Blood Research
|July 29, 2020
PubMed
Summary
This summary is machine-generated.

Extranodal NK/T cell lymphoma (ENKTL) treatment has advanced, improving outcomes for localized and advanced stages. However, refractory or recurrent ENKTL still requires novel therapeutic strategies.

Keywords:
ENKTLExtranodal natural killer/T cell lymphomaImmunotherapyNon-Hodgkin’s lymphoma

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.7K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.5K

Related Experiment Videos

Last Updated: Dec 13, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.5K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.7K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.5K

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare Non-Hodgkin's lymphoma primarily affecting the nasal region.
  • Treatment paradigms have evolved significantly, incorporating chemotherapy, radiotherapy, L-asparaginase, and immune checkpoint inhibitors.

Purpose of the Study:

  • To review current treatment strategies for ENKTL.
  • To discuss emerging therapeutic approaches for ENKTL.

Main Methods:

  • Literature review of treatment strategies for ENKTL.
  • Analysis of treatment outcomes based on disease stage and refractory status.

Main Results:

  • Combined chemotherapy and radiotherapy achieve high cure rates (>70%) in localized ENKTL.
  • L-asparaginase-containing regimens have improved outcomes for advanced ENKTL.
  • Patients with refractory or recurrent ENKTL still face poor prognoses.

Conclusions:

  • Current treatments offer curative potential for early-stage ENKTL.
  • Advances in L-asparaginase and immunotherapy have benefited advanced ENKTL.
  • Further research into novel treatments is crucial for refractory and recurrent ENKTL.